Roche Holding stock adds Alzheimer trial details before CTAD

Roche is expanding its Alzheimer pipeline before the Clinical Trials on Alzheimer’s Disease congress in Boston. In a release dated Tuesday, November 10, the group said it would present pharmaceutical and diagnostic updates from November 16 to 19.

The new detail is the TARBELA-AD program, a Phase II study of the investigational oral NLRP3 inhibitor RG6434 in people with early symptomatic Alzheimer’s disease. The study targets neuroinflammation alongside Roche’s existing work on amyloid biology. Roche’s CTAD release also lists a presentation on early safety data and the rationale and design of the trial.

CTAD sets the next milestones

Roche plans updated Phase Ib/IIa Brainshuttle AD findings for trontinemab, including data on amyloid removal, biomarkers, pharmacokinetics, pharmacodynamics and safety. The company also plans to discuss the Phase III PrevenTRON study, which has begun enrolling cognitively unimpaired participants with Alzheimer’s biomarkers and a high risk of clinical decline.

Diagnostics are part of the same conference program. Roche will present clinical, health-economic and real-world analyses for its Elecsys pTau217 and pTau181 blood tests, including their use in primary and specialist care.

Roche Holding stock traded at 440.70 euros on Lang & Schwarz at 18:17 CET on Thursday, November 12, 2026.

The Swiss market remains the relevant equity-market context for Roche investors. See the SMI market overview for broader regional developments.

More news and analyses on Roche Holding stock will follow the company’s upcoming presentations.